These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23741320)

  • 21. Phosphatidylinositol 3-kinase-dependent activation of mammalian protein kinase B/Akt in Saccharomyces cerevisiae, an in vivo model for the functional study of Akt mutations.
    Rodríguez-Escudero I; Andrés-Pons A; Pulido R; Molina M; Cid VJ
    J Biol Chem; 2009 May; 284(20):13373-13383. PubMed ID: 19307184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
    De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
    Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
    Mancini ML; Lien EC; Toker A
    Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.
    Mahajan P; Wadhwa B; Barik MR; Malik F; Nargotra A
    Mol Divers; 2020 Feb; 24(1):45-60. PubMed ID: 30798436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion.
    Wang S; Basson MD
    Exp Cell Res; 2008 Jan; 314(2):286-96. PubMed ID: 17825284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1 in Juvenile Granulosa Cell Tumors.
    Bessière L; Todeschini AL; Auguste A; Sarnacki S; Flatters D; Legois B; Sultan C; Kalfa N; Galmiche L; Veitia RA
    EBioMedicine; 2015 May; 2(5):421-31. PubMed ID: 26137586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity.
    Oeck S; Al-Refae K; Riffkin H; Wiel G; Handrick R; Klein D; Iliakis G; Jendrossek V
    Sci Rep; 2017 Feb; 7():42700. PubMed ID: 28209968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane.
    Berndt N; Yang H; Trinczek B; Betzi S; Zhang Z; Wu B; Lawrence NJ; Pellecchia M; Schönbrunn E; Cheng JQ; Sebti SM
    Cell Death Differ; 2010 Nov; 17(11):1795-804. PubMed ID: 20489726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AKT1 (E17K) mutation in pancreatic cancer.
    Mohamedali A; Lea NC; Feakins RM; Raj K; Mufti GJ; Kocher HM
    Technol Cancer Res Treat; 2008 Oct; 7(5):407-8. PubMed ID: 18783292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
    Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
    Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.
    Mahmoud IS; Sughayer MA; Mohammad HA; Awidi AS; EL-Khateeb MS; Ismail SI
    Br J Cancer; 2008 Aug; 99(3):488-90. PubMed ID: 18665177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
    Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
    Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
    He Y; Zheng J; Hu Y; Xiao H; Liu J; Li X; Du W; Chen X; Hu Y; Huang S
    Eur J Haematol; 2010 Jan; 84(1):87-8. PubMed ID: 19744127
    [No Abstract]   [Full Text] [Related]  

  • 37. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
    BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206.
    Rehan M; Beg MA; Parveen S; Damanhouri GA; Zaher GF
    PLoS One; 2014; 9(10):e109705. PubMed ID: 25329478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ca(2+)/calmodulin directly interacts with the pleckstrin homology domain of AKT1.
    Dong B; Valencia CA; Liu R
    J Biol Chem; 2007 Aug; 282(34):25131-40. PubMed ID: 17580302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.